Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02784496 · ClinicalTrials.gov registry record · Phase 2
Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT02784496: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02784496 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 8 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02784496, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
Primary Outcome
A review of the most common adverse events related to study medication will be performed. Will follow standard reporting guidelines for adverse events. Safety data will be summarized by the number of participants affected.
Interventions
- OTHER Quality-of-Life Assessment
- DRUG Ruxolitinib
- OTHER Long-term Follow-up
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2016-09-29 |
| Est. Completion | 2024-01-23 |
| Phase | Phase 2 |
What the finished NCT02784496 record still lists
NCT02784496 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02784496 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02784496 about?
NCT02784496 is a clinical study titled "Long-Term Side Effects of Ruxolitinib in Treating Patients With Myelofibrosis". This phase II trial studies the long-term side effects of ruxolitinib in treating patients with myelofibrosis. Collecting data about the long-term safety and tolerability of ruxolitinib may better help future patients with myelofibrosis.
What is the current status of trial NCT02784496?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2016-09-29. Estimated completion is 2024-01-23.
What interventions are being tested in trial NCT02784496?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Ruxolitinib (DRUG), Long-term Follow-up (OTHER).
Who is sponsoring clinical trial NCT02784496?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02784496's enrollment target sits among peer trials
8 1990th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI